Adjuvant radiotherapy versus concurrent chemoradiotherapy for the management of high-risk salivary gland carcinomas

Head & Neck ◽  
2016 ◽  
Vol 38 (11) ◽  
pp. 1628-1633 ◽  
Author(s):  
Matthew J. Mifsud ◽  
Tawee Tanvetyanon ◽  
Judith C. Mccaffrey ◽  
Kristen J. Otto ◽  
Tapan A. Padhya ◽  
...  
Keyword(s):  
Salivary Gland ◽  
High Risk ◽  
Adjuvant Radiotherapy ◽  
Concurrent Chemoradiotherapy ◽  
Salivary Gland Carcinomas

scholarly journals Management of Non-High-Risk Salivary Gland Carcinomas With Surgery Alone

Cureus ◽  
2021 ◽  
Author(s):  
Sepehr Shabani ◽  
Abhay V Sharma ◽  
Matthew L Carmichael ◽  
Tapan A Padhya ◽  
Matthew J Mifsud
Keyword(s):  
Salivary Gland ◽  
High Risk ◽  
Salivary Gland Carcinomas

scholarly journals Concurrent Chemoradiotherapy in the Adjuvant Treatment of High-risk Primary Salivary Gland Malignancies

2018 ◽  
Vol 41 (9) ◽  
pp. 888-893 ◽  
Author(s):  
Brian J. Gebhardt ◽  
James P. Ohr ◽  
Robert L. Ferris ◽  
Umamaheswar Duvvuri ◽  
Seungwon Kim ◽  
...  
Keyword(s):  
Salivary Gland ◽  
High Risk ◽  
Adjuvant Treatment ◽  
Concurrent Chemoradiotherapy

scholarly journals Perioperative treatments for stage IB–IIB uterine cervical cancer

2019 ◽  
Vol 50 (2) ◽  
pp. 99-103
Author(s):  
Muneaki Shimada ◽  
Hideki Tokunaga ◽  
Hiroaki Kobayashi ◽  
Mitsuya Ishikawa ◽  
Nobuo Yaegashi
Keyword(s):  
Cervical Cancer ◽  
High Risk ◽  
Neoadjuvant Chemotherapy ◽  
Radical Hysterectomy ◽  
Adjuvant Radiotherapy ◽  
Concurrent Chemoradiotherapy ◽  
Risk Groups ◽  
Perioperative Chemotherapy ◽  
Stage Ib ◽  
Risk Patients

Abstract Japan Society of Gynecologic Oncology guidelines recommended either radical hysterectomy-based approach or the definitive radiotherapy including concurrent chemoradiotherapy as primary treatment for patients with not only stage IB1/IIA1, but also stages IB2, IIA2 and IIB. Based on pathological findings of surgical specimens, patients who underwent radical hysterectomy are divided into three recurrent-risk groups, low-risk, intermediate, and high-risk groups. Although some authors reported the usefulness of adjuvant chemotherapy for intermediate/high-risk patients, radiotherapy was standard adjuvant treatment for pathological-risk patients after radical hysterectomy. It has been uncertain whether neoadjuvant chemotherapy followed by radical hysterectomy is beneficial for stage IB2–IIB patients. Recently, the randomized phase III study revealed that neoadjuvant chemotherapy followed by radical hysterectomy failed to improve survival of stage IB2–IIB patients compared to concurrent chemoradiotherapy. Majority of stage IB2–IIB patients are required adjuvant radiotherapy after radical hysterectomy. The multimodality strategy consisting of radical hysterectomy followed by adjuvant radiotherapy is associated with not only impaired quality of life, but also conflicting of cost-effectiveness. Thereby, some authors investigated the significance of multimodality strategy consisting of chemotherapy before/after radical hysterectomy for stage IB2–IIB cervical cancer. Multimodality strategy consisting of radical hysterectomy/perioperative chemotherapy needs higher curability of radical hysterectomy, higher response to perioperative chemotherapy and less perioperative complications. Consequently, gynecologic oncologists have to examine the patients strictly before treatment and judge whether radical hysterectomy-based approach or definitive irradiation is appropriate for the patient with stage IB–IIB cervical cancer.

PO-0804: Adjuvant radiotherapy in the management of major salivary gland tumors – Retrospective analysis

2020 ◽  
Vol 152 ◽  
pp. S436
Author(s):  
A. Florindo ◽  
S. Saraiva ◽  
T.C. Tomás ◽  
A. Abrunhosa-Branquinho ◽  
V. Mendonça ◽  
...  
Keyword(s):  
Salivary Gland ◽  
Retrospective Analysis ◽  
Adjuvant Radiotherapy ◽  
Salivary Gland Tumors ◽  
Major Salivary Gland

Immunohistochemical Expression of Fatty Acid Synthase (FASN) is Correlated to Tumor Aggressiveness and Cellular Differentiation in Salivary Gland Carcinomas

2021 ◽  
Author(s):  
Camila Matsunaga de Angelis ◽  
Reydson Alcides de Lima-Souza ◽  
João Figueira Scarini ◽  
Erika Said Abu Egal ◽  
Gleyson Kleber do Amaral-Silva ◽  
...  
Keyword(s):  
Salivary Gland ◽  
Fatty Acid ◽  
Cellular Differentiation ◽  
Fatty Acid Synthase ◽  
Tumor Aggressiveness ◽  
Immunohistochemical Expression ◽  
Salivary Gland Carcinomas

High expression level of geminin predicts a poor clinical outcome in salivary gland carcinomas

2010 ◽  
Vol 56 (7) ◽  
pp. 883-892 ◽  
Author(s):  
Manabu Yamazaki ◽  
Satoshi Fujii ◽  
Yukinori Murata ◽  
Ryuichi Hayashi ◽  
Atsushi Ochiai
Keyword(s):  
Salivary Gland ◽  
Clinical Outcome ◽  
High Expression ◽  
Expression Level ◽  
Poor Clinical Outcome ◽  
Salivary Gland Carcinomas ◽  
High Expression Level
Sign in / Sign up

Export Citation Format

Share Document